Skip to main content

Advertisement

SpringerLink
Log in

Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Micallef IN, Chhanabhai M, Gascoyne RD, Shepherd JD, Fung HC, Nantel SH et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998; 22: 981–987.

    Article  CAS  PubMed  Google Scholar 

  2. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69–76.

    Article  CAS  PubMed  Google Scholar 

  3. Cohen JM, Cooper N, Chakrabarti S, Thomson K, Samarasinghe S, Cubitt D et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48: 256–269.

    Article  PubMed  Google Scholar 

  4. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874–2880.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hale G, Waldmann H . Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998; 91: 3079–3083.

    CAS  PubMed  Google Scholar 

  6. Gazitt Y, Or R, Mumcuoglu M, Slavin S . Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells. Bone Marrow Transplant 1987; 2: 427–433.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Haematology, Nottingham University Hospitals-City Hospital Campus, Nottingham, UK

    S W Bokhari, E Das-Gupta, N H Russell & J Byrne

Authors
  1. S W Bokhari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Das-Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N H Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Byrne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S W Bokhari.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bokhari, S., Das-Gupta, E., Russell, N. et al. Post-transplant lymphoproliferative disease following reduced intensity conditioning transplants incorporating alemtuzumab. Bone Marrow Transplant 42, 281–282 (2008). https://doi.org/10.1038/bmt.2008.149

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.149

  • Springer Nature Limited

This article is cited by

Search

Navigation